| Record ID | marc_columbia/Columbia-extract-20221130-009.mrc:49198905:3156 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-009.mrc:49198905:3156?format=raw |
LEADER: 03156fam a2200481 a 4500
001 4047508
005 20221027024236.0
008 941028t19951995nyuo 001 0 eng c
010 $a 94043202
020 $a0679424652
035 $a(OCoLC)31608154
035 $a(OCoLC)ocm31608154
035 $9AKN0119HS
035 $a(NNC)4047508
035 $a4047508
040 $aDNLM/DLC$cDLC$dDLC$dNNC-M$dOrLoB
050 00 $aRC382$b.L37 1995
060 10 $aWL 359 L295c 1995
082 00 $a616.8/33$220
100 1 $aLangston, J. W.$q(James William)$0http://id.loc.gov/authorities/names/n86137690
245 14 $aThe case of the frozen addicts /$cJ. William Langston and Jon Palfreman.
260 $aNew York :$bPantheon Books,$c[1995], ©1995.
300 $aix, 309 pages :$billustrations ;$c24 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
500 $aIncludes index.
520 $aIn the summer of 1982, hospital emergency rooms in the San Francisco Bay Area were suddenly confronted with mysteriously "frozen" patients - young men and women who, though conscious, could neither move nor speak. Doctors were baffled, until neurologist J. William Langston, recognizing the symptoms of advanced Parkinson's disease, administered L-dopa - the only known effective treatment - and "unfroze" his patient.
520 8 $aDr. Langston determined that this patient and five others had all used the same tainted batch of synthetic heroin, inadvertently laced with a toxin that had destroyed an area of their brains essential to normal movement. This same area, the substantia nigra, slowly deteriorates in Parkinson's disease.
520 8 $aAs scientists raced to capitalize on this breakthrough, Dr. Langston struggled to salvage the lives of his frozen patients, for whom L-dopa provided only short-term relief. The solution he found lay in the most daring area of research: fetal-tissue transplants.
520 8 $aThe astonishing recovery of two of his patients garnered worldwide press coverage, helped overturn federal restrictions on fetal-tissue research, and offered hope to millions suffering from Parkinson's, Alzheimer's, and other degenerative brain disorders.
650 0 $aParkinson's disease$vCase studies.
650 0 $aMethylphenyltetrahydropyridine$xPhysiological effect.
650 0 $aDesigner drugs$xToxicology.
650 0 $aFetal tissues$xTransplantation$vCase studies.
650 0 $aParkinson's disease$xAnimal models.$0http://id.loc.gov/authorities/subjects/sh2009002641
650 12 $aParkinson Disease$xtherapy.$0https://id.nlm.nih.gov/mesh/D010300Q000628
650 22 $aFetal Tissue Transplantation.$0https://id.nlm.nih.gov/mesh/D016332
650 22 $aBrain Tissue Transplantation.$0https://id.nlm.nih.gov/mesh/D016380
650 22 $aSubstantia Nigra$xembryology.$0https://id.nlm.nih.gov/mesh/D013378Q000196
650 22 $aSubstantia Nigra$xtransplantation.$0https://id.nlm.nih.gov/mesh/D013378Q000637
655 7 $aCase Reports.$2mesh$0https://id.nlm.nih.gov/mesh/D002363
700 1 $aPalfreman, Jon.$0http://id.loc.gov/authorities/names/n94803264
852 00 $boff,hsl$hRC382$i.L37 1995